Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/23743
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMamo, David-
dc.contributor.authorSedman, Ewen-
dc.contributor.authorTillner, Joachim-
dc.contributor.authorSellers, Edward M.-
dc.contributor.authorRomach, Myroslava K.-
dc.contributor.authorKapur, Shitij-
dc.date.accessioned2017-11-13T14:11:29Z-
dc.date.available2017-11-13T14:11:29Z-
dc.date.issued2004-
dc.identifier.citationMamo, D., Sedman, E., Tillner, J., Sellers, E. M., Romach, M. K., & Kapur, S. (2004). EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study. Psychopharmacology, 175(3), 382-388.en_GB
dc.identifier.urihttps://www.um.edu.mt/library/oar//handle/123456789/23743-
dc.description.abstractWhile serotonin 5HT2-receptors have been im- plicated in the etiology and pharmacological treatment of a number of neuropsychiatric conditions, there are few potent and specific agents available for use in human clinical studies. EMD 281014 is a highly specific 5HT2- receptor antagonist that is currently under development. To find optimal doses for early clinical studies, we conducted a PET study using [18F]setoperone in nine healthy subjects scanned at baseline and following the administration of 1, 3, and 7 mg EMD 281014. The study drug was well tolerated by all study participants, and all doses resulted in 70% occupancy at frontal 5HT2- receptors 3 h after drug administration. The data suggest that daily dosing of 3 mg EMD 281014 should be sufficient to provide sustained high levels of 5HT2- receptor occupancy in future clinical trials.en_GB
dc.language.isoenen_GB
dc.publisherSpringeren_GB
dc.rightsinfo:eu-repo/semantics/restrictedAccessen_GB
dc.subjectTomography, Emissionen_GB
dc.subjectClinical trialsen_GB
dc.titleEMD 281014, a specific and potent 5HT2 antagonist in humans : a dose-finding PET studyen_GB
dc.typearticleen_GB
dc.rights.holderThe copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holderen_GB
dc.description.reviewedpeer-revieweden_GB
dc.identifier.doi10.1007/s00213-004-1817-7-
dc.publication.titlePsychopharmacologyen_GB
Appears in Collections:Scholarly Works - FacM&SPsy

Files in This Item:
File Description SizeFormat 
10.10072Fs00213-004-1817-7.pdf
  Restricted Access
299.6 kBAdobe PDFView/Open Request a copy


Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.